Article

Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family

UCSF Memory and Aging Center, University of California-San Francisco, CA 94143, USA.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 5.58). 02/2011; 82(2):196-203. DOI: 10.1136/jnnp.2009.204081
Source: PubMed

ABSTRACT Frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) is a heritable form of FTD, but the gene(s) responsible for the majority of autosomal dominant FTD-ALS cases have yet to be found. Previous studies have identified a region on chromosome 9p that is associated with FTD and ALS.
The authors report the clinical, volumetric MRI, neuropathological and genetic features of a new chromosome 9p-linked FTD-ALS family, VSM-20.
Ten members of family VSM-20 displayed heterogeneous clinical phenotypes of isolated behavioural-variant FTD (bvFTD), ALS or a combination of the two. Parkinsonism was common, with one individual presenting with a corticobasal syndrome. Analysis of structural MRI scans from five affected family members revealed grey- and white-matter loss that was most prominent in the frontal lobes, with mild parietal and occipital lobe atrophy, but less temporal lobe atrophy than in 10 severity-matched sporadic bvFTD cases. Autopsy in three family members showed a consistent and unique subtype of FTLD-TDP pathology. Genome-wide linkage analysis conclusively linked family VSM-20 to a 28.3 cM region between D9S1808 and D9S251 on chromosome 9p, reducing the published minimal linked region to a 3.7 Mb interval. Genomic sequencing and expression analysis failed to identify mutations in the 10 known and predicted genes within this candidate region, suggesting that next-generation sequencing may be needed to determine the mutational mechanism associated with chromosome 9p-linked FTD-ALS.
Family VSM-20 significantly reduces the region linked to FTD-ALS on chromosome 9p. A distinct pattern of brain atrophy and neuropathological findings may help to identify other families with FTD-ALS caused by this genetic abnormality.

Download full-text

Full-text

Available from: Ging-Yuek Robin Hsiung, Aug 20, 2015
1 Follower
 · 
296 Views
  • Source
    • " This suggests that TDP - 43 - mediated neurodegeneration contributes to the development of disease , as in sporadic ALS and FTLD - TDP . Furthermore , atypical ubiquitin / p62 - positive , but TDP - 43 - negative , neuronal inclusions with - in cerebellar granules cells and hippocampal pyramidal neurons are observed ( Al - Sarraj et al . , 2011 ; Boxer et al . , 2011 ; Murray et al . , 2011 ) . This unique and highly characteristic feature suggests that C9ORF72 mutations cause the abnormal accumulation of yet - to - be identified ubiquitinated proteins . The involvement of these proteina - ceous aggregates in disease pathogenesis has yet to be elucidated . Using a semi - quantitative , repeat - prim"
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular viability depends upon the well-orchestrated functions carried out by numerous protein-coding and non-coding RNAs, as well as RNA-binding proteins. During the last decade, it has become increasingly evident that abnormalities in RNA processing represent a common feature among many neurodegenerative diseases. In "RNAopathies", which include diseases caused by non-coding repeat expansions, RNAs exert toxicity via diverse mechanisms: RNA foci formation, bidirectional transcription, and the production of toxic RNAs and proteins by repeat associated non-ATG translation. The mechanisms of toxicity in "RNA-binding proteinopathies", diseases in which RNA-binding proteins like TDP-43 and FUS play a prominent role, have yet to be fully elucidated. Nonetheless, both loss of function of the RNA binding protein, and a toxic gain of function resulting from its aggregation, are thought to be involved in disease pathogenesis. As part of the special issue on RNA and Splicing Regulation in Neurodegeneration, this review intends to explore the diverse RNA-related mechanisms contributing to neurodegeneration, with a special emphasis on findings emerging from animal models.
    Molecular and Cellular Neuroscience 12/2012; 56. DOI:10.1016/j.mcn.2012.12.006 · 3.73 Impact Factor
  • Source
    • "A pathological expansion of a hexanucleotide G 4 C 2 repeat in the promoter region of the gene C9orf72 (MIM #614260) was recently identified as the long sought-after underlying gene defect [Dejesus- Hernandez et al., 2011; Gijselinck et al., 2012; Renton et al., 2011] of linkage [Boxer et al., 2011; Gijselinck et al., 2010; Luty et al., 2008; Le Ber et al., 2009; Morita et al., 2006; Pearson et al., 2011; Vance et al., 2006; Valdmanis et al., 2008] and association [Laaksovirta et al., 2010; Shatunov et al., 2010; van Es et al., 2009; Van Deerlin et al., 2010] of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) to the chromosome 9p21 region [Van Langenhove et al., 2012a]. In the Flanders-Belgian population, we calculated that the pathological G 4 C 2 expansion is the second most common genetic cause of FTLD [Gijselinck et al., 2012; Van Langenhove et al., 2012b]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We assessed the geographical distribution of C9orf72 G(4) C(2) expansions in a pan-European frontotemporal lobar degeneration (FTLD) cohort (n = 1205), ascertained by the European Early-Onset Dementia (EOD) consortium. Next, we performed a meta-analysis of our data and that of other European studies, together 2,668 patients from 15 Western European countries. The frequency of the C9orf72 expansions in Western Europe was 9.98% in overall FTLD, with 18.52% in familial, and 6.26% in sporadic FTLD patients. Outliers were Finland and Sweden with overall frequencies of respectively 29.33% and 20.73%, but also Spain with 25.49%. In contrast, prevalence in Germany was limited to 4.82%. In addition, we studied the role of intermediate repeats (7 to 24 repeat units), which are strongly correlated with the risk haplotype, on disease and C9orf72 expression. In vitro reporter gene expression studies demonstrated significantly decreased transcriptional activity of C9orf72 with increasing number of normal repeat units, indicating that intermediate repeats might act as predisposing alleles and in favor of the loss-of-function disease mechanism. Further, we observed a significantly increased frequency of short indels in the GC-rich low complexity sequence (LCS) adjacent to the G(4) C(2) repeat in C9orf72 expansion carriers (p < 0.001) with the most common indel creating one long contiguous imperfect G(4) C(2) repeat which is likely more prone to replication slippage and pathological expansion.
    Human Mutation 10/2012; 34(2). DOI:10.1002/humu.22244 · 5.05 Impact Factor
  • Source
    • "The neuropathological findings were consistent with type B FTLD-TDP pathology, with characteristic ubiquitin-and p62-pathology in the granular layer of the cerebellar cortex, in all except for two brains. This cerebellar pathology has been found in other families with FTD + ALS with the pathogenic repeat expansion (Polvikoski et al., 2003; Boxer et al., 2011; Dejesus-Hernandez et al., 2011; Renton et al., 2011), and in a series of patients with FTD + ALS or FTLD-TDP (King et al., 2011). Our observation confirms its strong association with the pathogenic repeat expansion, but it is not an absolute requisite for this disorder. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is increasing evidence that frontotemporal dementia and amyotrophic lateral sclerosis are part of a disease continuum. Recently, a hexanucleotide repeat expansion in C9orf72 was identified as a major cause of both sporadic and familial frontotemporal dementia and amyotrophic lateral sclerosis. The aim of this study was to investigate clinical and neuropathological characteristics of hexanucleotide repeat expansions in C9orf72 in a large cohort of Dutch patients with frontotemporal dementia. Repeat expansions were successfully determined in a cohort of 353 patients with sporadic or familial frontotemporal dementia with or without amyotrophic lateral sclerosis, and 522 neurologically normal controls. Immunohistochemistry was performed in a series of 10 brains from patients carrying expanded repeats using a panel of antibodies. In addition, the presence of RNA containing GGGGCC repeats in paraffin-embedded sections of post-mortem brain tissue was investigated using fluorescence in situ hybridization with a locked nucleic acid probe targeting the GGGGCC repeat. Hexanucleotide repeat expansions in C9orf72 were found in 37 patients with familial (28.7%) and five with sporadic frontotemporal dementia (2.2%). The mean age at onset was 56.9 ± 8.3 years (range 39-76), and disease duration 7.6 ± 4.6 years (range 1-22). The clinical phenotype of these patients varied between the behavioural variant of frontotemporal dementia (n = 34) and primary progressive aphasia (n = 8), with concomitant amyotrophic lateral sclerosis in seven patients. Predominant temporal atrophy on neuroimaging was present in 13 of 32 patients. Pathological examination of the 10 brains from patients carrying expanded repeats revealed frontotemporal lobar degeneration with neuronal transactive response DNA binding protein-positive inclusions of variable type, size and morphology in all brains. Fluorescence in situ hybridization analysis of brain material from patients with the repeat expansion, a microtubule-associated protein tau or a progranulin mutation, and controls did not show RNA-positive inclusions specific for brains with the GGGGCC repeat expansion. The hexanucleotide repeat expansion in C9orf72 is an important cause of frontotemporal dementia with and without amyotrophic lateral sclerosis, and is sometimes associated with primary progressive aphasia. Neuropathological hallmarks include neuronal and glial inclusions, and dystrophic neurites containing transactive response DNA binding protein. Future studies are needed to explain the wide variation in clinical presentation.
    Brain 03/2012; 135(Pt 3):723-35. DOI:10.1093/brain/awr353 · 10.23 Impact Factor
Show more